Ariad Pharmaceuticals (NASDAQ:ARIA) and Exelixis (NASDAQ:EXEL) have both stumbled, with bad news causing significant drops in share price over the past year (Ariad has lost over 60% of its value, while Exelixis is down 30% over the last year and over 60% from its 52-week high at the beginning of 2014).
Ariad had issues with its drug Iclusig, which was pulled from the market by the FDA due to safety issues, and has now returned with stronger warning labels and a reduced market potential. Investors were hoping that Exelixis' Cometriq, which is currently approved for thyroid cancer, would be so effective in a prostate cancer trial that the trial would be stopped early. That didn't happen.
With both stocks down badly from their 52-week highs, which is the better bad news buy?
In the video below, Motley Fool health care analysts Michael Douglass and David Williamson tell you which, and why.
Of course, there may be even better opportunities out there. Try this top stock on for size.
Give me five minutes and I'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks 1 stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.
David Williamson has no position in any stocks mentioned. Michael Douglass has no position in any stocks mentioned. The Motley Fool recommends Exelixis. The Motley Fool owns shares of Exelixis. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.